Dialog Box

PET scans eligible for Medicare rebates for rare cancer patients

Positron emission tomography (PET) scans can more accurately stage certain cancers leading to better treatment decisions, patient outcomes and cost-effectiveness. However, when only a small number of people have a specific type of cancer it has been difficult to gather enough evidence to properly assess these outcomes.

Recognising this, it was recently announced that a new Medicare Benefits Schedule (MBS) item will be introduced for PET scans for initial staging of patients with eligible rare and uncommon cancers. This new item will be introduced from 1 November 2022.

An eligible cancer type is:

  • a rare or uncommon cancer (<12 per 100,000/year) and
  • normally expected to be an FDG-avid cancer, where there is at least a 10% likelihood that the PET study result will inform a significant change in management for the patient

More information

For more information, please visit the MSAC website.

Learn more

08 September 2022
Category: News